Abstract 3120
Background
Immune-checkpoint inhibitors have revolutionized advanced melanoma care. Despite major improvements in survival, many patients do not derive long-term benefit and treatment could cause severe side-effects. Since several new (combination) therapies are or will become available, early prediction of non-responsiveness (NR) to anti-PD-1 monotherapy becomes relevant in order to enable early switch to next line (combination) treatment and avoid nonsensical care.
Methods
Advanced melanoma patients treated with pembrolizumab (PEM) who started PEM between June 2014 and August 2016 were included in this retrospective analysis. S100 and lactate dehydrogenase (LDH) levels were routinely determined prior to initiation of PEM and every 3-weeks during treatment. NR to treatment was defined as progressive disease or death at 6 months after start of PEM. Biomarker response characteristic (BReC) plots were obtained and LDH and S100 response cut-offs were determined based on two criteria: specificity for NR > 95% and feasibility to use in clinical practice. Next, sensitivity, specificity and predictive values were generated per follow-up time point (week 3, 6, 9, 12 and 15).
Results
166 advanced melanoma patients were included. The BReC analyses showed clear relations between an early (week 3 to 15) increase in tumor biomarker and NR. An increase of > 50% in LDH or a > 100% increase in S100 above the upper limit of normal compared to baseline at any follow-up interval was determined as criterion to positively test for NR. Obtained specificity ranged from 0.97-0.98 and the positive predictive value ranged from 0.92-0.96 for the studied follow-up intervals. Obtained sensitivity for detecting non-responsiveness ranged from 0.25 (95% CI; 0.16-0.35) at 3 weeks of follow-up to 0.35 (95% CI; 0.24-0.47) at 12 weeks of follow-up.
Conclusions
An early increase in S100 and/or LDH are strong parameters for non-responsiveness to PD-1 blockade in advanced melanoma. Prospective confirmation is needed before clinical implementation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Netherlands Cancer Institute.
Funding
Netherlands Cancer Institute.
Disclosure
E.A. Rozeman: Travel / Accommodation / Expenses: NanoString; Travel / Accommodation / Expenses: MSD. J.V. van Thienen: Advisory / Consultancy: Pfizer; Advisory / Consultancy: Novartis. J.B.A.G. Haanen: Advisory / Consultancy, Research grant / Funding (institution): BMS; Advisory / Consultancy, Research grant / Funding (institution): MSD; Advisory / Consultancy: Pfizer; Advisory / Consultancy: AZ/MedImmune; Advisory / Consultancy: Roche/Genentech; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Bayer; Advisory / Consultancy: Immunocore; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Neon Therapeutics; Advisory / Consultancy: Celsius; Advisory / Consultancy: Seattle Genetics; Advisory / Consultancy: Gadet. C.U. Blank: Advisory / Consultancy, Research grant / Funding (institution): BMS; Advisory / Consultancy: MSD; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Lilly ; Advisory / Consultancy: GSK; Advisory / Consultancy: GenMab; Research grant / Funding (institution): NanoString; Advisory / Consultancy: Roche; Advisory / Consultancy: Pierre Fabre. All other authors have declared no conflicts of interest.
Resources from the same session
4634 - Comparative molecular analyses between microsatellite stable BRAFV600E mutant colorectal cancers and BRAFV600E mutant melanomas.
Presenter: Mohamed Salem
Session: Poster Display session 3
Resources:
Abstract
3264 - A novel preclinical model of RAF-independent MEK1 mutant tumors and its treatment with novel ATP competitive MEK inhibitor
Presenter: Luca Hegedus
Session: Poster Display session 3
Resources:
Abstract
4918 - HER2 inhibition in Aggressive Squamous Cell Carcinomas driven by a common MET Sema Domain Polymorphism
Presenter: Nur Afiqah Mohamed Salleh
Session: Poster Display session 3
Resources:
Abstract
2426 - ADAM9 as a target for lung cancer treatment
Presenter: Yuh-pyng Sher
Session: Poster Display session 3
Resources:
Abstract
5537 - Novel polyurea/polyurethane nanocapsules loaded with a tambjamine analog to improve cancer chemotherapy delivery and safety in lung cancer
Presenter: Marta Perez Hernandez
Session: Poster Display session 3
Resources:
Abstract
1597 - Discovery of Clinical Candidate DBPR112, a Furanopyrimidine-based Epidermal Growth Factor Receptor Inhibitor for the Treatment of Non-Small Cell Lung Cancer
Presenter: Hsing-pang Hsieh
Session: Poster Display session 3
Resources:
Abstract
3543 - Molecular characteristics in lung squamous cell carcinomas dependent on TP53 status – putative targets
Presenter: Vilde Haakensen
Session: Poster Display session 3
Resources:
Abstract
4111 - Comparison of molecular profiles between primary tumour and matched metastasis in non-small cell lung cancer
Presenter: Asuka Kawachi
Session: Poster Display session 3
Resources:
Abstract
4559 - Treatment with BLU-667, a potent and selective RET inhibitor, provides rapid clearance of ctDNA in Patients with RET-altered Non-Small Cell Lung Cancer (NSCLC) and Thyroid Cancer
Presenter: Giuseppe Curigliano
Session: Poster Display session 3
Resources:
Abstract
2501 - Triple MET/SRC/PIM inhibition in MET addicted tumors
Presenter: Ilaria Attili
Session: Poster Display session 3
Resources:
Abstract